Skip to content
Comparison

GHRP-2 vs Ipamorelin

GHRP-2 and Ipamorelin are commonly compared for potency versus selectivity in GHRP protocols. GHRP-2 is usually favored for higher GH pulse intensity, while Ipamorelin is often preferred for lower cortisol/prolactin spillover. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For potency versus selectivity in GHRP protocols, the better choice depends on your primary endpoint. GHRP-2 is stronger when the priority is users needing stronger secretagogue drive. Ipamorelin is stronger when the priority is users prioritizing tolerability and cleaner profile. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaGHRP-2Ipamorelin
Primary mechanismPotent ghrelin-receptor GH secretagogueSelective GHS-R1a agonist (GHRP) with lower cortisol/prolactin signal
Strongest clinical signalHigh GH pulse amplitude vs several older analogsReliable GH pulse support with cleaner endocrine profile than older GHRPs
Typical dosing context100-300 mcg 1-3 times daily100-300 mcg, often 1-3 times daily
AdministrationSubcutaneous injectionSubcutaneous injection
Evidence quality gradeModerate class evidenceModerate mechanistic and clinical support
Regulatory statusResearch-use peptideNot FDA-approved; clinic/research use
Side-effect burdenCan raise appetite, cortisol, and prolactinGenerally mild side effects when appropriately dosed
Cost/access contextModerate pricing in peptide channelsVariable clinic and compounding pricing
Best candidate profileUsers seeking stronger GH pulse intensity than ipamorelinUsers seeking GH support with fewer appetite/cortisol issues
Main limitationSelectivity and tolerability weaker than ipamorelinEvidence depth below approved endocrine therapies
Best use case in this comparisonusers needing stronger secretagogue driveusers prioritizing tolerability and cleaner profile

When to Choose Each

Choose GHRP-2

Best for users needing stronger secretagogue drive.

Choose Ipamorelin

Best for users prioritizing tolerability and cleaner profile.

Verdict

If the main goal is users needing stronger secretagogue drive, GHRP-2 is usually the better first-line choice. If the main goal is users prioritizing tolerability and cleaner profile, Ipamorelin is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Dose-dependent GH-releasing effects of GHRP-2 in healthy adult men (1997) — PubMed
  2. GHRP-2 (pralmorelin) as a diagnostic tool for growth hormone deficiency: clinical validation (2001) — PubMed
  3. Comparative effects of growth hormone secretagogues on GH, cortisol, and prolactin release in humans (2005) — PubMed
  4. Dipeptidyl peptidase IV resistant analogues of growth hormone-releasing hormone (2005) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for potency versus selectivity in GHRP protocols — GHRP-2 or Ipamorelin?
GHRP-2 is graded as moderate class evidence evidence in this context, while Ipamorelin is graded as moderate mechanistic and clinical support. In practice, strength depends on whether you prioritize users needing stronger secretagogue drive or users prioritizing tolerability and cleaner profile. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can GHRP-2 and Ipamorelin be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next